Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mental Magnesium (also marketed as Mental-Mag) is a brain health dietary supplement developed by Triquetra Health. Launched in July 2026, it is formulated as a dual-pathway brain magnesium system designed to support memory, focus, sleep quality, and stress resilience. The product combines two patented, blood-brain barrier-crossing forms of magnesium: Magtein (Magnesium L-Threonate) and ATA Mg (Magnesium N-Acetyl Taurinate). These are paired with a precision cofactor matrix consisting of active Pyridoxal-5-Phosphate (Vitamin B6), Vitamin D3, Magnesium Ascorbate (Vitamin C), and a Fulvic/Humic Mineral Complex. Together, these ingredients work synergistically to optimize brain magnesium levels, support healthy neurotransmitter activity, and promote cognitive performance and relaxation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mental Magnesium.